search
Back to results

Exercise Dosing Trial for Individuals With Parkinson's Disease (PDEX)

Primary Purpose

Parkinsons Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
High-intensity, aerobic exercise.
Sponsored by
University of Virginia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Parkinsons Disease focused on measuring Exercise

Eligibility Criteria

45 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects with idiopathic Parkinson Disease as determined by United Kingdom Brain Bank Criteria. This includes the presence of bradykinesia with one or both of the following: rest tremor and/or rigidity
  • Asymmetric onset of PD and progressive motor symptoms.
  • Hoehn and Yahr stage 2 or 3.
  • Stable dopaminergic medication regimen for 4 weeks prior to baseline visit with no anticipated changes for the duration of the study.
  • Stable doses of medications known to affect sleep and medications for Parkinson's Disease for at least 4 weeks prior to study entry without anticipation of medication change for the duration of the study.
  • Ability to complete exercise intervention and assessment visits during at least 16 weeks of intervention (3x/week for 16 weeks).
  • Must pass a physical examination to assess exercise readiness.
  • Women of childbearing potential may enroll but must use a reliable measure of contraception and have a negative serum pregnancy test at the screening visit.
  • Montreal Cognitive Assessment score ≥ 18 and ≤30.
  • Ability to pass a Physical Activity Readiness Questionnaire to assess exercise readiness.

Exclusion Criteria:

  • Atypical features indicative of a Parkinson's Plus disorder (Progressive Supranuclear Palsy, Multiple Systems Atrophy, Corticobasal Degeneration) including cerebellar signs, supranuclear gaze palsy, apraxia, prominent autonomic failure, or other cortical signs.
  • Neuroleptic treatment at time of onset of Parkinsonism
  • Active treatment with a neuroleptic at time of study entry. Exceptions to this are quetiapine and clozapine.
  • History of multiple strokes with stepwise progression of Parkinsonism
  • History of multiple head injuries
  • Inability to walk without assistance, including a cane, wheelchair, or walker
  • Regular participation in an exercise program within the past 6 months.
  • Deep Brain Stimulation or other neurosurgical procedure for PD.
  • Untreated sleep apnea
  • Known narcolepsy
  • Participation in drug studies or the use of investigational drugs within 30 days prior to screening
  • Acute illness or active, confounding medical, neurological, or musculoskeletal conditions that, at the discretion of the PI, would prevent the subject's ability to participate in the study
  • Known contraindication to testing
  • Active alcoholism or other drug addiction
  • Pregnancy
  • Moderate to severe dementia

Sites / Locations

  • University of Virginia Health System

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

High-intensity aerobic exercise

Arm Description

Subjects will participate in a 16 week high-intensity aerobic exercise program.

Outcomes

Primary Outcome Measures

Global Composite Cognitive Score

Secondary Outcome Measures

Full Information

First Posted
February 1, 2016
Last Updated
November 1, 2022
Sponsor
University of Virginia
search

1. Study Identification

Unique Protocol Identification Number
NCT02676804
Brief Title
Exercise Dosing Trial for Individuals With Parkinson's Disease
Acronym
PDEX
Official Title
Exercise Dosing Trial for Individuals With Parkinson's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
March 2016 (undefined)
Primary Completion Date
August 2019 (Actual)
Study Completion Date
August 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Virginia

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, pre-post intervention study to evaluate the effect of a high-intensity, aerobic exercise program on outcomes of cognition, mood, gait, balance, cardiorespiratory fitness, neuromuscular performance, fatigue, sleep, and quality of life for patients diagnosed with idiopathic Parkinson disease. The primary outcomes will be a composite measure of cognitive function and the Timed Up and Go (TUG).
Detailed Description
All subjects will be assigned to aerobic exercise that will use a blend of both unsupervised moderate and supervised high intensity exercise. The exercise will consist of walking / jogging modalities, dependent on the individual's level of bradykinesia and will be paced by the individual's level of perceived exertion. The exercise protocol will be designed to target an accumulation of at least 150 minutes of cardiovascular exercise per week. Exercise training will be performed 5x/week for a total of 16 weeks. The training will consist of 3 supervised high intensity sessions and 2 at home moderate intensity exercise sessions. The high intensity sessions will be performed on a treadmill at an intensity rating of ~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of ~10 - 12 and participants will be asked to complete this on their own.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinsons Disease
Keywords
Exercise

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High-intensity aerobic exercise
Arm Type
Experimental
Arm Description
Subjects will participate in a 16 week high-intensity aerobic exercise program.
Intervention Type
Other
Intervention Name(s)
High-intensity, aerobic exercise.
Intervention Description
Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week. Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of ~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of ~10 - 12 and participants will be asked to complete this on their own.
Primary Outcome Measure Information:
Title
Global Composite Cognitive Score
Time Frame
16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects with idiopathic Parkinson Disease as determined by United Kingdom Brain Bank Criteria. This includes the presence of bradykinesia with one or both of the following: rest tremor and/or rigidity Asymmetric onset of PD and progressive motor symptoms. Hoehn and Yahr stage 2 or 3. Stable dopaminergic medication regimen for 4 weeks prior to baseline visit with no anticipated changes for the duration of the study. Stable doses of medications known to affect sleep and medications for Parkinson's Disease for at least 4 weeks prior to study entry without anticipation of medication change for the duration of the study. Ability to complete exercise intervention and assessment visits during at least 16 weeks of intervention (3x/week for 16 weeks). Must pass a physical examination to assess exercise readiness. Women of childbearing potential may enroll but must use a reliable measure of contraception and have a negative serum pregnancy test at the screening visit. Montreal Cognitive Assessment score ≥ 18 and ≤30. Ability to pass a Physical Activity Readiness Questionnaire to assess exercise readiness. Exclusion Criteria: Atypical features indicative of a Parkinson's Plus disorder (Progressive Supranuclear Palsy, Multiple Systems Atrophy, Corticobasal Degeneration) including cerebellar signs, supranuclear gaze palsy, apraxia, prominent autonomic failure, or other cortical signs. Neuroleptic treatment at time of onset of Parkinsonism Active treatment with a neuroleptic at time of study entry. Exceptions to this are quetiapine and clozapine. History of multiple strokes with stepwise progression of Parkinsonism History of multiple head injuries Inability to walk without assistance, including a cane, wheelchair, or walker Regular participation in an exercise program within the past 6 months. Deep Brain Stimulation or other neurosurgical procedure for PD. Untreated sleep apnea Known narcolepsy Participation in drug studies or the use of investigational drugs within 30 days prior to screening Acute illness or active, confounding medical, neurological, or musculoskeletal conditions that, at the discretion of the PI, would prevent the subject's ability to participate in the study Known contraindication to testing Active alcoholism or other drug addiction Pregnancy Moderate to severe dementia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Harrison B Madaline, MD
Organizational Affiliation
University of Virginia
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Virginia Health System
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22908
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
If data is shared, Investigators plan to obtain a material transfer agreement.

Learn more about this trial

Exercise Dosing Trial for Individuals With Parkinson's Disease

We'll reach out to this number within 24 hrs